Gilead Sciences (GILD) Revenue — Quarter Ended Dec 31, 2024
Revenue increased year-over-year and showed a modest sequential gain. The annual growth was more pronounced compared to the modest rise from the immediate prior quarter.
Key takeaway
Quarter ended Dec 31, 2024 · FY2024 Q4
Revenue increased year-over-year and showed a modest sequential gain. The annual growth was more pronounced compared to the modest rise from the immediate prior quarter.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$7.6B
Revenue reported for this quarter.
Quarter-over-quarter
+0.3%
Change from the immediately preceding quarter.
Year-over-year
+6.4%
Change from the comparable year-ago quarter.
Trailing four quarters
$28.8B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2024 | $6.7B | +5.3% |
| Jun 30, 2024 | $7B | +5.4% |
| Sep 30, 2024 | $7.5B | +7.0% |
| Dec 31, 2024 | $7.6B | +6.4% |
Revenue performance
For the quarter, revenue continued its upward trajectory, reaching a new high in the trailing twelve months.
Quarterly comparison
Compared to the preceding quarter, revenue increased slightly. On a year-over-year basis, the growth was stronger, reflecting a higher rate of expansion.
What to watch
The sequential growth rate decelerated significantly from prior quarters within the fiscal year.